94201-40-8

Usage

Uses

Used in Pharmaceutical Industry:
1-Phenylpiperidine-4-carboxylic acid is used as a key intermediate for the synthesis of pharmaceutical drugs. Its unique structural properties and reactivity contribute to the development of various medications, making it an essential component in drug production.
Used in Organic Synthesis:
1-Phenylpiperidine-4-carboxylic acid is used as a building block in organic synthesis. Its versatility and reactivity allow for the creation of a wide range of chemical compounds, further expanding its applications in the pharmaceutical and chemical industries.

InChI:InChI=1/C12H15NO2/c14-12(15)10-6-8-13(9-7-10)11-4-2-1-3-5-11/h1-5,10H,6-9H2,(H,14,15)

Upstream product

• 857806-58-7 1-phenyl-piperidine-4-carboxylic acid anilide 
• 857778-39-3 4-bromo-2-(2-bromo-ethyl)-butyric acid ethyl ester 
• 1126-09-6 4-carbethoxypiperidine 
• 591-50-4 iodobenzene 
• 2971-79-1 isonipecotic acid methyl ester 
• 498-94-2 isonipecotic acid 
• 247022-37-3 ethyl 1-phenylpiperidine-4-carboxylate 
• 62-53-3 aniline 

Downstream Products

• 697308-32-0 N-[(1R,2S)-1-[({3-[(dimethylamino)methyl]phenyl}amino)carbonyl]-2-(1H-indol-3-yl)propyl]-1-phenylpiperidine-4-carboxamide 
• 1449132-89-1 1-phenylpiperidine-4-carbonyl chloride 
• 888038-17-3 1-phenyl-piperidine-4-carboxylic acid (3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)-amide 
• 1596371-66-2 N-(4-(4-(2-(tert-butyl)-6-(trifluoromethyl)pyrimidin-4-yl)piperazin-1-yl)butyl)-1-phenylpiperidine-4-carboxamide 
• 1446690-50-1 1-phenylpiperidine-4-carboxylic acid hydrazide 
• 374887-16-8 4-[5-ethyl-4-(2-fluorophenyl)-4H-1,2,4-triazol-3-yl]-1-phenylpiperidine 

Relevant academic research and scientific papers

Beyond Basicity: Discovery of Nonbasic DENV-2 Protease Inhibitors with Potent Activity in Cell Culture

The viral serine protease NS2B-NS3 is one of the promising targets for drug discovery against dengue virus and other flaviviruses. The molecular recognition preferences of the protease favor basic, positively charged moieties as substrates and inhibitors, which leads to pharmacokinetic liabilities and off-target interactions with host proteases such as thrombin. We here present the results of efforts that were aimed specifically at the discovery and development of noncharged, small-molecular inhibitors of the flaviviral proteases. A key factor in the discovery of these compounds was a cellular reporter gene assay for the dengue protease, the DENV2proHeLa system. Extensive structure-activity relationship explorations resulted in novel benzamide derivatives with submicromolar activities in viral replication assays (EC50 0.24 μM), selectivity against off-target proteases, and negligible cytotoxicity. This structural class has increased drug-likeness compared to most of the previously published active-site-directed flaviviral protease inhibitors and includes promising candidates for further preclinical development.

1, 4-DISUBSTITUTED PIPERIDINES AS VASOPRESSIN RECEPTOR VIA ANTAGONISTS

The present invention provides compounds of formula (1) compositions comprising such compounds; the use of such compounds in therapy (such as in the treatment of dysmenorrhoea); and methods of treating patients with such compounds; wherein A and G are as defined herein.

4-Piperidinecarboxamide modulators of vanilloid VR1 receptor

This invention is directed to vanilloid receptor VR1 ligands. More particularly, this invention relates to hetero isonipecotic amides that are potent modulators of VR1 which are useful for the treatment and prevention of disease conditions in mammals.

TETRAHYDRO-NAPHTHALENE AND UREA DERIVATIVES

This invention relates to a hydroxy-tetrahydro-naphthalene or an urea derivative formula (I) and salts thereof which are useful as active ingredients of pharmaceutical preparations, wherein A represents formula (II) or (III) wherein # represents the connection position to the molecule and Q1a, Q2a, Q3a and Q4a are defined, and E represents formula (IV) or (V) wherein # represents the connection position to the molecule and Q1b, Q2b, Q3b, Q4b, Q5b, R1b, na, ma, Xa and Ra are defined.

INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE

The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras